Table of Content


List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Tyrosine Protein Kise CSK (C Src Kise or Protein Tyrosine Kise CYL or CSK or EC 2.7.10.2) - Overview
Tyrosine Protein Kise CSK (C Src Kise or Protein Tyrosine Kise CYL or CSK or EC 2.7.10.2) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Products under Development by Universities/Institutes
Tyrosine Protein Kise CSK (C Src Kise or Protein Tyrosine Kise CYL or CSK or EC 2.7.10.2) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Tyrosine Protein Kise CSK (C Src Kise or Protein Tyrosine Kise CYL or CSK or EC 2.7.10.2) - Companies Involved in Therapeutics Development
Athenex Inc
Nuvectis Pharma Inc
Pulmatrix Inc
Tyrosine Protein Kise CSK (C Src Kise or Protein Tyrosine Kise CYL or CSK or EC 2.7.10.2) - Drug Profiles
KX-2361 - Drug Profile
Product Description
Mechanism Of Action
History of Events
NXP-900 - Drug Profile
Product Description
Mechanism Of Action
History of Events
PP-1 - Drug Profile
Product Description
Mechanism Of Action
PUR-1800 - Drug Profile
Product Description
Mechanism Of Action
History of Events
Small Molecules to Inhibit C Src Kise for Colon Cancer - Drug Profile
Product Description
Mechanism Of Action
Small Molecules to Inhibit CSK for Oncology - Drug Profile
Product Description
Mechanism Of Action
History of Events
Synthetic Peptide to Inhibit Src Tyrosine Kise for Prostate Cancer - Drug Profile
Product Description
Mechanism Of Action
tirbanibulin - Drug Profile
Product Description
Mechanism Of Action
History of Events
UM-164 - Drug Profile
Product Description
Mechanism Of Action
Tyrosine Protein Kise CSK (C Src Kise or Protein Tyrosine Kise CYL or CSK or EC 2.7.10.2) - Dormant Products
Tyrosine Protein Kise CSK (C Src Kise or Protein Tyrosine Kise CYL or CSK or EC 2.7.10.2) - Discontinued Products
Tyrosine Protein Kise CSK (C Src Kise or Protein Tyrosine Kise CYL or CSK or EC 2.7.10.2) - Product Development Milestones
Featured News & Press Releases
Oct 18, 2022: Nuvectis Phrama announces poster presentation at the 34th EORTC-NCI-AACR Symposium on molecular targets and cancer therapeutics
Aug 18, 2022: Almirall’s Klisyri (tirbanibulin) receives strong recommendation in American Academy of Dermatology AK guideline update
Jun 22, 2022: Athenex announces sale of revenues from U.S. and European Royalty and Milestone Interests in Klisyri (tirbanibulin) to Sagard Healthcare partners and Oaktree
Apr 13, 2022: Nuvectis Pharma recaps Poster Presentation highlights for NXP900 at the 2022 American Association for Cancer Research (AACR) Conference
Mar 21, 2022: Pulmatrix announces positive top-line data evaluating PUR1800 in Patients with Stable COPD
Mar 10, 2022: Nuvectis announces upcoming oral and poster presentations at the 2022 American Association for Cancer Research Meeting
Feb 22, 2022: Nuvectis announces positive data for NXP900 in triple negative breast cancer preclinical models with an Integrin-Linked Kise (ILK) Loss
Sep 27, 2021: Almirall launches Klisyri(Tirbanibulin) for the treatment of actinic keratosis in Europe
Jul 19, 2021: Almirall receives European Commission approval of Klisyri (tirbanibulin), an innovative topical treatment for actinic keratosis
May 21, 2021: Almirall receives positive CHMP opinion for Klisyri (tirbanibulin), an innovative topical treatment for actinic keratosis
Apr 12, 2021: Pulmatrix to regain full rights to PUR1800 and rrow spectrum kise inhibitor portfolio
Mar 04, 2021: Pulmatrix provides update on its lung cancer drug candidate PUR-1800
Feb 18, 2021: Almirall U.S. launches Klisyri (tirbanibulin), a new, innovative topical treatment for actinic keratosis
Feb 18, 2021: Athenex announces U.S. launch of Klisyri and licensing of additiol territories for tirbanibulin
Feb 11, 2021: Athenex announces New England Jourl of Medicine publication of phase III data on the efficacy and safety of Klisyri (tirbanibulin)
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer



List of Figures

List of Figures
Number of Products under Development by Stage of Development, 2022
Number of Products under Development by Therapy Areas, 2022
Number of Products under Development by Top 10 Indications, 2022
Number of Products by Mechanism of Actions, 2022
Number of Products by Stage and Mechanism of Actions, 2022
Number of Products by Top 10 Routes of Administration, 2022
Number of Products by Stage and Top 10 Routes of Administration, 2022
Number of Products by Top 10 Molecule Types, 2022
Number of Products by Stage and Top 10 Molecule Types, 2022

List of Tables

List of Tables
Number of Products under Development by Stage of Development, 2022
Number of Products under Development by Therapy Areas, 2022
Number of Products under Development by Indication, 2022
Number of Products under Development by Companies, 2022
Products under Development by Companies, 2022
Products under Development by Companies, 2022 (Contd..1)
Number of Products under Investigation by Universities/Institutes, 2022
Products under Investigation by Universities/Institutes, 2022
Number of Products by Stage and Mechanism of Actions, 2022
Number of Products by Stage and Route of Administration, 2022
Number of Products by Stage and Molecule Type, 2022
Pipeline by Athenex Inc, 2022
Pipeline by Nuvectis Pharma Inc, 2022
Pipeline by Pulmatrix Inc, 2022
Dormant Products, 2022
Dormant Products, 2022 (Contd..1)
Discontinued Products, 2022